Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
01/19/20179:00AMBWOpdivo (nivolumab) Demonstrated Efficacy & Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a...
Opdivo demonstrated a 37% reduction in the risk of death compared to placebo 12-month overall survival rates were 26.6% in Opdivo-treated patients compared to 10.9% in placebo-treated patients Bristol-Myers Squibb Company (NYSE:BMY) announced today the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly... More...>>
01/11/20174:17PMDJNTrump Attacks Drugmakers on Pricing
By Joseph Walker Donald Trump attacked the pharmaceutical industry on Wednesday in his first press conference as president-elect, accusing drugmakers of "getting away with murder" and pledging to "save billions of dollars" by changing how the U.S. purchases drugs. "Pharma has a lot of lobbies... More...>>
01/06/20176:59AMBWBristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration
GeneCentric secures equity investment from Bristol-Myers Squibb Bristol-Myers Squibb to explore the use of GeneCentric’s Cancer Subtyping Platform (CSP™) Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of... More...>>
01/05/20176:59AMBWBristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combinatio...
Phase 1b/2 studies to explore a novel Immuno-Oncology combination in hematological and solid tumors with high unmet medical need. Builds off previous clinical collaboration between the companies Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate... More...>>
01/04/20174:05PMGLOBEFive Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Ther...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option... More...>>
01/03/20179:18AMBWBristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, in San Francisco. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 9:30 a.m. PST (12:30 p.m. EST). Investors and the general public are invited to listen... More...>>
12/29/20169:00AMBWBristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2017, in Boston, Massachusetts. Giovanni Caforio, M.D., chief executive officer, will answer questions about the company at 9:30 a.m. EST. Investors and the general public... More...>>
12/21/201610:18AMDJNBristol-Myers Names CEO Giovanni Caforio as New Chairman
By Anne Steele Bristol-Myers Squibb Co. on Wednesday said Chief Executive Giovanni Caforio will add the chairman title this spring, succeeding Lamberto Andreotti, who will retire. The switch, which will be effective at the May 2 shareholder meeting, marks the final exit of one of the leaders who helped transform the pharmaceutical... More...>>
12/21/20168:30AMBWGiovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
Caforio will Succeed Lamberto Andreotti Effective May 2, 2017 Bristol-Myers Squibb Company (NYSE:BMY) today announced that the company’s Board of Directors has appointed Giovanni Caforio, M.D. as chairman of the board, effective May 2, the date of the company’s annual meeting of shareholders. Caforio, who will continue... More...>>
12/21/20166:59AMGLOBEBristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination ...
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology... More...>>
12/21/20166:59AMBWBristol-Myers Squibb & Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination wi...
Study to evaluate potential of CB-839 plus Opdivo to target immune-suppressive cells in the tumor microenvironment Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against... More...>>
12/20/20166:59AMBWBristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolyt...
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors. The agreement is subject to clearance under the... More...>>
12/19/20168:00AMGLOBEPortola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced it has signed a $50 million loan agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) that provides additional funding toward development and clinical studies of AndexXa™... More...>>
12/19/20164:28AMDJNBeximco Pharmaceuticals Gets U.S. Approval for Diabetes Control Drug
By Philip Waller LONDON--Shares in Beximco Pharmaceuticals Ltd (BXP.LN) rose 7.4% on Monday after it said U.S. regulators have given it the go-ahead to market its extended-release Metformin tablets for diabetes control. The generic drug manufacturer said the U.S. Food & Drug Administration has approved 500 milligram... More...>>
12/13/20169:30AMBWBristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint
Bristol-Myers Squibb Company (NYSE:BMY) today announced important changes to its U.S. geographic footprint that will strengthen capabilities of the company's R&D hubs of world-class science and innovation in Central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts while further integrating biologics... More...>>
12/09/20164:00PMBWBristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2016 on Thursday, January 26, 2017. During a conference call at 10:30 a.m. EST on January 26, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public... More...>>
12/08/20164:15PMBWBristol-Myers Squibb Announces Dividend Increase
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.6% percent in the company’s quarterly dividend, beginning in the first quarter of 2017. The dividend increase will result in a quarterly dividend of thirty nine cents ($0.39) per share on the $.10 par value Common Stock... More...>>
12/06/20168:45AMBWOpdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response & Survival Rates in Recurrent Small ...
Objective response rate with Opdivo plus Yervoy was 25% and was 11% with Opdivo monotherapy; in the combination arm, three patients experienced a complete response Estimated two-year survival rate with the combination was 30% and was 17% with Opdivo monotherapy No new safety signals were observed with Opdivo and Opdivo... More...>>
12/06/20162:50AMDJNU.S. 'Disappointed' by Japan's Plan to Cut Drug Costs
TOKYO—The U.S. government has written to a senior aide of Japan's Prime Minister Shinzo Abe, calling on Tokyo to reconsider a plan that would allow more frequent pharmaceutical price cuts. The letter from Secretary of Commerce Penny Pritzker describes how the U.S. is "disappointed" by the Japanese... More...>>
12/05/20167:30PMBWSeattle Genetics & Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin)...
– Combination Data Showed 90 Percent Objective Response Rate and 62 Percent Complete Response Rate with an Acceptable Safety Profile in Pre-Transplant Relapsed or Refractory Classical Hodgkin Lymphoma Patients – – Data Support Continued Clinical Investigation of ADCETRIS and Opdivo Combination in Hodgkin Lymphoma... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20170119 17:02:48